A Phase 1 Multiple Ascending Oral Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

Trial Profile

A Phase 1 Multiple Ascending Oral Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs ASP 4345 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 12 Sep 2017 Status changed from recruiting to completed.
    • 20 Jun 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.
    • 20 Jun 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top